In addition, the downregulation of PDCD5 has been observed in multiple types of cancers, such as breast cancer (Hedenfalk et al. 2001), ovarian carcinoma (Zhang et al. 2011), gastric cancer (Yang et al. 2006), hepatocellular carcinoma (Fu et al. 2013; Xu et al. 2001), acute and chronic myeloid leukemia (Ruan et al. 2006), glioma (Li et al. 2008) and laryngeal squamous cell carcinoma (Xu et al. 2013), and correlates with tumor progression and prognosis. Here, PDCD5 is linked to central nervous system cancer.